a good fit for the rare disease drugs from GSK. Aside from Strimvelis, Orchard gets two late-stage clinical programmes in ongoing registrational studies for metachromatic leukodystrophy (MLD ...
GlaxoSmithKline’s gene therapy Strimvelis for the treatment of the ultra-rare ‘bubble baby syndrome’ has been approved by NICE. The one-off therapy costs €594,000, equivalent to £505,000 ...
Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback